Literature DB >> 11069208

Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes.

R Lugari1, C Dell'Anna, D Ugolotti, A Dei Cas, A L Barilli, R Zandomeneghi, B Marani, M Iotti, A Orlandini, A Gnudi.   

Abstract

Exogenous glucagon-like peptide 1(GLP-1) bioactivity is preserved in type 2 diabetic patients, resulting the peptide administration in a near-normalization of plasma glucose mainly through its insulinotropic effect. GLP-1 also reduces meal-related insulin requirement in type 1 diabetic patients, suggesting an impairment of the entero-insular axis in both diabetic conditions. To investigate this metabolic dysfunction, we evaluated endogenous GLP-1 concentrations, both at fasting and in response to nutrient ingestion, in 16 type 1 diabetic patients (age = 40.5 +/- 14yr, HbA1C = 7.8 +/- 1.5%), 14 type 2 diabetics (age = 56.5 +/- 13yr, HbA1C = 8.1 +/- 1.8%), and 10 matched controls. In postabsorptive state, a mixed breakfast (230 KCal) was administered to all subjects and blood samples were collected for plasma glucose, insulin, C-peptide and GLP-1 determination during the following 3 hours. In normal subjects, the test meal induced a significant increase of GLP-1 (30', 60': p < 0.01), returning the peptide values towards basal concentrations. In type 2 diabetic patients, fasting plasma GLP-1 was similar to controls (102.1 +/- 1.9 vs. 97.3 +/- 4.01 pg/ml), but nutrient ingestion failed to increase plasma peptide levels, which even decreased during the test (p < 0.01). Similarly, no increase in postprandial GLP-1 occurred in type 1 diabetics, in spite of maintained basal peptide secretion (106.5 +/- 1.5 pg/ml). With respect to controls, the test meal induced in both diabetic groups a significant increase in plasma glucagon levels at 60' (p < 0.01). In conclusion, either in condition of insulin resistance or insulin deficiency chronic hyperglycemia, which is a common feature of both metabolic disorders, could induce a progressive desensitization of intestinal L-cells with consequent peptide failure response to specific stimulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11069208     DOI: 10.1055/s-2007-978665

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  16 in total

1.  Energy homeostasis and body weight in obesity: new physiopathological and therapeutic considerations.

Authors:  G Magnati; A Dei Cas
Journal:  Eat Weight Disord       Date:  2000-09       Impact factor: 4.652

Review 2.  Molecular defects in insulin secretion in type-2 diabetes.

Authors:  Frances M Ashcroft; Patrik Rorsman
Journal:  Rev Endocr Metab Disord       Date:  2004-05       Impact factor: 6.514

3.  Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus.

Authors:  E Mannucci; L Pala; S Ciani; G Bardini; A Pezzatini; I Sposato; F Cremasco; A Ognibene; C M Rotella
Journal:  Diabetologia       Date:  2005-04-29       Impact factor: 10.122

Review 4.  Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes.

Authors:  Jeff Unger
Journal:  Curr Diab Rep       Date:  2013-10       Impact factor: 4.810

Review 5.  Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus.

Authors:  Claire M Issa; Sami T Azar
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

6.  The Incretins and Pancreatic beta-Cells: Use of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide to Cure Type 2 Diabetes Mellitus.

Authors:  Mi-Hyun Kim; Moon-Kyu Lee
Journal:  Korean Diabetes J       Date:  2010-02-28

7.  Islet cell antibody-positive versus -negative phenotypic type 2 diabetes in youth: does the oral glucose tolerance test distinguish between the two?

Authors:  Hala Tfayli; Fida Bacha; Neslihan Gungor; Silva Arslanian
Journal:  Diabetes Care       Date:  2009-12-22       Impact factor: 17.152

Review 8.  Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies.

Authors:  S Calanna; M Christensen; J J Holst; B Laferrère; L L Gluud; T Vilsbøll; F K Knop
Journal:  Diabetologia       Date:  2013-02-03       Impact factor: 10.122

9.  Effects of meal size on the release of GLP-1 and PYY after Roux-en-Y gastric bypass surgery in obese subjects with or without type 2 diabetes.

Authors:  Wen Yan; David Polidori; Lynn Yieh; Jianing Di; Xiaodong Wu; Veronica Moreno; Lina Li; Celia P Briscoe; Nigel Shankley; G Lynis Dohm; Walter J Pories
Journal:  Obes Surg       Date:  2014-11       Impact factor: 4.129

Review 10.  Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.

Authors:  George G Holz; Oleg G Chepurny
Journal:  Curr Med Chem       Date:  2003-11       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.